Evidence map›Paper›PMID 34180759›Full record

ArticleBioengineered2021

Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Wenguang Wang, Zhilu Gan, Qiang Liu, Shenshen Yan, Rexiti Mulati, Yujie Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in molecular biosciences · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wenguang WangDepartment of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Zhilu GanDepartment of Urology, The Third People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Qiang LiuDepartment of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Shenshen YanDepartment of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Rexiti MulatiDepartment of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yujie WangDepartment of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.ORCID 0000-0003-4326-720X
Xinjiang Medical University · CNPeople's Hospital of Xinjiang Uygur Autonomous Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant expression of the chemokine CXC receptor 4 (CXCR4) is closely associated with cancer progression and drug-resistance in multiple cancers, and we first investigated the role of CXCR4 in regulating cancer pathogenesis and cisplatin (DDP)-resistance in clear cell renal cell carcinoma (ccRCC) in the present study. Here, we identified that CXCR4 acted as an oncogene to promote cancer progression and genetically silencing of CXCR4 increased cisplatin (DDP)-sensitivity in ccRCC

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationCisplatinDrug Resistance, NeoplasmGene SilencingHumansMaleMiceMice, NudeReceptors, CXCR4Antineoplastic AgentsCisplatinCXCR4 protein, humanReceptors, CXCR4cancer biologychemokine receptor 4cisplatin-sensitivityClear cell renal cell carcinoma

Identifiers

PMID34180759
PMCPMC8806489
OpenAlexW3175235339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.